Cargando…

969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines

BACKGROUND: Despite the risks of immunosuppression, recommendations regarding screening for HIV infection prior to initiation of biologic therapies targeting common autoimmune disorders, including inflammatory bowel disease (IBD) and inflammatory arthritides, are limited. Few cases of patients start...

Descripción completa

Detalles Bibliográficos
Autores principales: Claytor, Jennifer, Viramontes, Omar, Conner, Stephanie, Wen, Kwun Wah, Beck, Kendall, Henrich, Timothy J, Chin-Hong, Peter, Peluso, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776272/
http://dx.doi.org/10.1093/ofid/ofaa439.1155
_version_ 1783630643534495744
author Claytor, Jennifer
Viramontes, Omar
Conner, Stephanie
Wen, Kwun Wah
Beck, Kendall
Henrich, Timothy J
Chin-Hong, Peter
Chin-Hong, Peter
Peluso, Michael J
author_facet Claytor, Jennifer
Viramontes, Omar
Conner, Stephanie
Wen, Kwun Wah
Beck, Kendall
Henrich, Timothy J
Chin-Hong, Peter
Chin-Hong, Peter
Peluso, Michael J
author_sort Claytor, Jennifer
collection PubMed
description BACKGROUND: Despite the risks of immunosuppression, recommendations regarding screening for HIV infection prior to initiation of biologic therapies targeting common autoimmune disorders, including inflammatory bowel disease (IBD) and inflammatory arthritides, are limited. Few cases of patients started on biologics while living with undiagnosed HIV have been reported. METHODS: We report 3 cases of patients initiated on biologics in the absence of recent or concurrent HIV screening who developed refractory disease or unanticipated complications and were later found to have undiagnosed chronic HIV infection. RESULTS: In Case 1, a 53-year-old man who has sex with men (MSM) with negative HIV testing 10 years prior presented with presumed rheumatoid arthritis. He did not respond to methotrexate (MTX), so adalimumab (ADA) was started. HIV testing to evaluate persistent symptoms was positive 9 months later; CD4 was 800 cells/uL. Antiretroviral therapy (ART) resulted in resolution of symptoms, which were attributed to HIV-associated arthropathy. In Case 2, a 55-year-old woman with injection drug use in remission and no prior HIV testing presented with Hidradenitis Suppurativa (HS). She was initiated on infliximab (IFX) and MTX with good response. After she developed weight loss and lymphopenia, an HIV test was positive; CD4 was 334 cells/uL. Biologic HS therapy was discontinued, with subsequent poor HS control. In Case 3, a 32-year-old MSM with no prior HIV testing presented with presumed IBD; IFX and steroids were started. Symptoms progressed despite IBD-directed therapy, and he was diagnosed with extensive Kaposi Sarcoma (KS) with visceral and cutaneous involvement likely exacerbated by immunosuppression. HIV testing was positive; CD4 was 250 cells/uL. KS initially worsened due to ART-associated immune reconstitution inflammatory syndrome. He is now improving with systemic chemotherapy and ART. HIV-associated KS is presumed to be hte underlying diagnosis. CONCLUSION: All 3 patients had elevated risk for HIV infection, and 2 had final diagnoses attributed to chronic HIV infection, not warranting therapeutic immunosuppression. Screening for HIV infection prior to initiation of biologic therapy should be incorporated into clinical practice guidelines. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776272
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77762722021-01-07 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines Claytor, Jennifer Viramontes, Omar Conner, Stephanie Wen, Kwun Wah Beck, Kendall Henrich, Timothy J Chin-Hong, Peter Chin-Hong, Peter Peluso, Michael J Open Forum Infect Dis Poster Abstracts BACKGROUND: Despite the risks of immunosuppression, recommendations regarding screening for HIV infection prior to initiation of biologic therapies targeting common autoimmune disorders, including inflammatory bowel disease (IBD) and inflammatory arthritides, are limited. Few cases of patients started on biologics while living with undiagnosed HIV have been reported. METHODS: We report 3 cases of patients initiated on biologics in the absence of recent or concurrent HIV screening who developed refractory disease or unanticipated complications and were later found to have undiagnosed chronic HIV infection. RESULTS: In Case 1, a 53-year-old man who has sex with men (MSM) with negative HIV testing 10 years prior presented with presumed rheumatoid arthritis. He did not respond to methotrexate (MTX), so adalimumab (ADA) was started. HIV testing to evaluate persistent symptoms was positive 9 months later; CD4 was 800 cells/uL. Antiretroviral therapy (ART) resulted in resolution of symptoms, which were attributed to HIV-associated arthropathy. In Case 2, a 55-year-old woman with injection drug use in remission and no prior HIV testing presented with Hidradenitis Suppurativa (HS). She was initiated on infliximab (IFX) and MTX with good response. After she developed weight loss and lymphopenia, an HIV test was positive; CD4 was 334 cells/uL. Biologic HS therapy was discontinued, with subsequent poor HS control. In Case 3, a 32-year-old MSM with no prior HIV testing presented with presumed IBD; IFX and steroids were started. Symptoms progressed despite IBD-directed therapy, and he was diagnosed with extensive Kaposi Sarcoma (KS) with visceral and cutaneous involvement likely exacerbated by immunosuppression. HIV testing was positive; CD4 was 250 cells/uL. KS initially worsened due to ART-associated immune reconstitution inflammatory syndrome. He is now improving with systemic chemotherapy and ART. HIV-associated KS is presumed to be hte underlying diagnosis. CONCLUSION: All 3 patients had elevated risk for HIV infection, and 2 had final diagnoses attributed to chronic HIV infection, not warranting therapeutic immunosuppression. Screening for HIV infection prior to initiation of biologic therapy should be incorporated into clinical practice guidelines. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776272/ http://dx.doi.org/10.1093/ofid/ofaa439.1155 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Claytor, Jennifer
Viramontes, Omar
Conner, Stephanie
Wen, Kwun Wah
Beck, Kendall
Henrich, Timothy J
Chin-Hong, Peter
Chin-Hong, Peter
Peluso, Michael J
969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title_full 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title_fullStr 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title_full_unstemmed 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title_short 969. TNF-alpha inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines
title_sort 969. tnf-alpha inhibition in the setting of undiagnosed hiv infection: a call for enhanced screening guidelines
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776272/
http://dx.doi.org/10.1093/ofid/ofaa439.1155
work_keys_str_mv AT claytorjennifer 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT viramontesomar 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT connerstephanie 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT wenkwunwah 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT beckkendall 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT henrichtimothyj 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT chinhongpeter 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT chinhongpeter 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines
AT pelusomichaelj 969tnfalphainhibitioninthesettingofundiagnosedhivinfectionacallforenhancedscreeningguidelines